Biotech | March 16, 2022
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
The investment will accelerate the overall Sarclisa development program
Tapestri Platform powers Nature Cardiovascular Research publication that identifies two somatic mutations associated with sporadic brain blood vessel disorder
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Tislelizumab is now approved for seven indications in China
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Subscribe To Our Newsletter & Stay Updated
